書籍詳細

臨床編

P.17 掲載の参考文献

• ○ 山口英世:病原真菌と真菌症 改訂4版, 南山堂, 東京, 2007, pp.96-101

• ○ 深在性真菌症の診断・治療ガイドライン, 深在性真菌症のガイドライン作成委員会編, 協和企画, 東京, 2007, pp.45-47

P.19 掲載の参考文献

• 1) Gefter WB:The spectrum of plumonary aspergillosis. J Thorac Imaging 7:56-74, 1992

• ○ Walsh TJ, Anaissie EJ, Denning DW et al:Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis 46:327-360, 2008

• ○ 深在性真菌症のガイドライン作成委員会:深在性真菌症の診断・治療ガイドライン 2007, 協和企画, 東京, 2007

P.23 掲載の参考文献

• ○ Pan American Health Organization:Polio Eradication Field Guide. Washington D.C., 1994

• ○ WHO:Polio. The beginning of the end, 1997, pp.16-17

• ○ Cutts FT:Advances and challenges for the expanded programme on immunization. Br Med Bull 54:445-461, 1998
  pubmed

P.25 掲載の参考文献

• 1) Siegel JD, Rhinehart E, Jackson M et al:Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for Isolation Precautions:Preventing Transmission of Infectious Agents in Healthcare Settings 2007 (http://www.cdc.gov/ncidod/dhqp/gl_isolation.html)

• 2) Pittet D, Allegranzi B, Sax H et al:Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect Dis 6:641-652, 2006
  pubmed

• 3) Kumar A, Roberts D, Wood KE et al:Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596, 2006
  pubmed

• 4) Dancer SJ:Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition:the case of hospital cleaning. Lancet Infect Dis 8:101-113, 2008
  pubmed

• 5) Loo VG, Poirier L, Miller MA et al:A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442-2449, 2005

P.27 掲載の参考文献

• 1) Henter JI, Horne A, Arico M et al:HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124-131, 2007
  pubmed

• 2) 津田弘之:ウイルス関連血球貧食症候群. Drug Delivery System 学会誌 23:71-73, 2008

• ○ Rouphael NG, Talati NJ, Vaughan C et al:Infections associated with haemophagocytic syndrome. Lancet Infect Dis 7:814-822, 2007
  pubmed

• ○ 津田弘之:血球貧食症候群の新展開. 血液フロンティア 17:741-750, 2007

P.32 掲載の参考文献

• 1) Widner AF, Frei R:Decontamination, disinfection, and sterilization. In:Manual of clinical microbiology 9th ed, ed. by Murray PR et al, ASM, Washington D.C., 2007, pp.65-96

• 2) 小林寛伊, 大久保憲, 尾家重治:改訂消毒と滅菌のガイドライン, へるす出版, 東京, 2004

• 3) Rutala WA:Disinfection, sterilization, and waste disposal. In:Prevention and control of nosocomial infections, ed. by Wenzel RP, Lippincott Williams & Wilkins, Baltimore, 1987, pp.247-282

• 4) 小林寛伊, 都築正和, 織田敏次ほか:B型肝炎ウイルスの不活性化. 医科器械学 50:524-525, 1980
  Medical*Online

• 5) 小林寛伊, 都築正和, 織田敏次ほか:B型肝炎ウイルスの滅菌, 消毒-チンパンジーによる検討. 外科 42:1526-1546, 1980

• 6) Bond WW, Favero MS, Petersen NJ et al:Inactivation of hepatitis B virus by intermediate-to-high-level disinfectant chemicals. J Clin Microbiol 18:535-538, 1983
  pubmed

• 7) Kobayashi H, Tsuzuki M, Koshimizu K et al:Susceptibility of hepatitis B virus to disinfectant or heat. J Clin Microbiol 20:214-216, 1984
  pubmed

• 8) Doultree JC, Druce JD, Birch CJ:Inactivation of feline calicivirus, a Norwalk virus surrogate. J Hosp Infect 41:51-57, 1999
  pubmed

• 9) Gehrke C, Steinmann J, Goroncy-Bermes P:Inactivation of feline calicivirus, a surrogate of norovirus (formerly Nowalk-like viruses), by different types of alcohol in vitro and in vivo. J Hosp Infect 56:49-55, 2004

• 10) Satter SA:Microbicides and the enviromental control of nosocomial viral Infections. J Hosp Infect 56:S64-S69, 2004

• 11) Kampf G, Grotheer D, Steinmann J:Efficacy of three ethanol-based hand rubs against feline calicivirus, a surrogate virus for norovirus. J Hosp Infect 60:144-149, 2005
  pubmed

• 12) Andrews S, Bauman L, Bidol S et al:Norovirus. Local Health Department Guideline for environmental cleaning and disinfection of norovirus May 2005 Version 2.0. Michigan 2005:Michigan Dept Community Health (MDCH). http://www.michigan.gov/documents/Guidelines_for_Environmental_Cleaning_125846_7.pdf

• 13) CDC:Norovirus in Healthcare Facilities Fact Sheet. CDC, Atlanta, 2006. http://www.cdc.gov/ncidod/dhqp/id_norovirusFS.html

P.35 掲載の参考文献

• 1) Salahuddin SZ, Ablashi DV, Markham PD et al:Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234:596-601, 1986
  pubmed

• 2) Yamanishi K, Okuno T, Shiraki K et al:Identification of human herpesvirus 6 as a causal agent for exanthem subitum. Lancet i:1065-1067, 1988
  pubmed

• 3) Frenkel N, Schirmer EC, Wyatt LS et al:Isolation of a new herpesvirus from human CD4+T cells. Proc Natl Acad Sci USA 87:748-752, 1990
  pubmed

• 4) Tanaka K, Kondo T, Torigoe S et al:Human herpesvirus 7:Another causal agent for roseola (exanthem subitum). J Pediatr 125:1-5, 1994
  pubmed

P.37 掲載の参考文献

• 1) Mandell GL, Bennett JE, Dolin R:Interpreting the Results of Clinical Trials on Antimicrobial Age. In:Principles and Practice of Infectious Diseases, Churchill Livingstone, New York, 2005

• 2) Blok WL, Gyssens IC, Hekster YA et al:Feasibility of an antibiotic order form. First experience in the department of internal medicine of a university hospital. Pharm World Sci 18:137-141, 1996
  pubmed

• 3) Thompson RL, Wright AJ:General principles of antimicrobial therapy. Mayo Clin Proc 73:995-1006, 1998
  pubmed

• 4) van der Meer JW, Gyssens IC:Quality of antimicrobial drug prescription in hospital Clin Microbiol Infect 7:12-15, 2001
  pubmed

P.41 掲載の参考文献

• 1) 柳原克紀, 河野茂:Vancomycin-resistant enterococci (VRE)に対する抗菌化学療法-リネゾリドを中心に-. 日本化学療法学会雑誌 50:633-639, 2002

• 2) Jones RN, Ross JE, Fritsche TR et al:Oxazolidinone susceptibility patterns in 2004:report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57:279-287, 2006

• ○ Yanagihara K, Kaneko Y, Sawai T et al:Efficacy of linezolid against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection. Antimicrob Agents Chemother 46:3288-3291, 2002

• ○ Wunderink RG, Rello J, Cammarata SK et al:Linezolid vs vancomycin:analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789-1797, 2003
  pubmed

P.43 掲載の参考文献

• ○ Green KY:Norovirus In:Fields Virology 5th ed, Lippincott Williams & Wilkins, Philadelphia, 2006, pp.841-874

• ○ 丸山務, 西尾治, 中村明子ほか:ノロウイルス現場対策, 幸書房, 東京, 2006

• ○ Nguyen TA, Khamrin P, Takanashi S et al:Evaluation of immunochromatography tests for detection of rotavirus and norovirus among Vietnamese children with acute gastroenteritis and the emergence of a novel norovirus G II. 4 variant J Trop Pediatr 53:264-269, 2007

P.45 掲載の参考文献

• ○ 山口英世:病原真菌と真菌症 改訂4版, 南山堂, 東京, 2007

• ○ 深在性真菌症のガイドライン作成委員会:深在性真菌症の診断・治療ガイドライン2007, 協和企画, 東京, 2007

• ○ Tortorano AM, Kibbler C, Peman J et al:Candidemia in Europe:epidemiology and resistance. Int J Antimicrob Agents 27:359-366, 2006

• ○ Falagas ME, Apostolou KE, Pappas VD:Attributable mortality of candidemia:a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25:419-425, 2006
  pubmed

P.47 掲載の参考文献

• 1) Bernard GR, Artigas A, Brigham KL et al:The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824, 1994
  pubmed

• 2) Steinberg KP, Hudson LD, Goodman RB et al:Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354:1671-1684, 2006
  pubmed

• 3) Minneci PC, Deans KJ, Banks SM et al:Meta-analysis:the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141:47-56, 2004

• 4) Tamakuma S, Ogawa M, Aikawa N et al:Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther 17:271-279, 2004
  pubmed

• 5) Brower RG, Lanken PN, MacIntyre N et al:Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 351:327-336, 2004
  pubmed

• 6) Wiedemann HP, Wheeler AP, Bernard GR et al:Comparison of two fluid-management strategies in lung injury. N Engl J Med 354:2564-2575, 2006
  pubmed

P.49 掲載の参考文献

• 1) Miyashita N, Fukano H, Yoshida K et al:Seroepidemiology of Chlamydia pneumoniae in Japan between 1991 and 2000. J Clin Pathol 55:115-117, 2002
  pubmed

• 2) Arnold FW, Summersqill JT, Lajoie AS et al:A worldwide perspective of atypical Pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 175:1086-1093, 2007

• ○ Miyashita N, Matsumoto A:Morphology of Chlamydia pneumoniae. In:Chlamydia pneumoniae infection and disease, ed. by Friedman H, Yamamoto Y, Bendinelli M, Kluwer Academic/Plenum Publishers, New York, 2004, pp.11-28

• ○ Miyashita N, Fukano H, Okimoto N et al:Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults. Chest 121:1776-1781, 2002
  pubmed

• ○ Miyashita N, Fukano H, Yoshida K et al:Chlamydia pneumoniae infection in adult patients with persistent cough. J Med Microbiol 52:265-269, 2003

• ○ Miyashita N, Niki Y, Nakajima M et al:Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults. Chest 119:1416-1419, 2001
  pubmed

• ○ Miyashita N, Ouchi K, Shoji H et al:Outbreak of Chlamydophila pneumoniae infection in long-term care facilities and an affiliated hospital. J Med Microbiol 54:1243-1247, 2005

P.51 掲載の参考文献

• 1) Kuroki M, Phichaichumpon C. Yasuoka A et al:Environmental isolation of Cryptococcus neoformans from an endemic region of HIV-associated cryptococcosis in Thailand. Yeast 21:809-812, 2004
  pubmed

• 2) Nosanchuk JD, Shoham S, Fries BC et al:Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 132:205-208, 2000

• 3) Nakamura S, Miyazaki Y, Higashiyama Y et al:Community acquired pneumonia (CAP) caused by Cryptococcus neoformans in a healthy individual. Scand J Infect Dis 37:932-935, 2005

• 4) 深在性真菌症のガイドライン作成委員会:深在性真菌症の診断・治療ガイドライン 2007, 協和企画, 東京, 2007, pp.8-13

• 5) Bicanic T, Meintjes G, Wood R et al:Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45:76-80, 2007

P.53 掲載の参考文献

• ○ Kato H, Kato N, Watanabe K et al:Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan. J Clin Microbiol 39:1391-1395, 2001
  pubmed

• ○ 加藤はる:Clostridium difficile関連下痢症-分子疫学と細菌学的検査-. JARMAM 14:121-126, 2003

• ○ 泉田さゆり, 加藤秀章, 橋本政治ほか:トキシンA検出キット, D1抗原検出キットおよび培養法によるClostridium difficile検出の比較検討. 日本消化器病学会雑誌 102:1004-1009, 2005
  Medical*Online

P.55 掲載の参考文献

• 1) The Working Group, on Severe Streptococcal Infections:Defining the group A streptococcal toxic shock syndrome. JAMA 269:390-391, 1993

• 2) 清水可方, 五十嵐英夫, 村井貞子ほか:本邦における劇症型A群レンサ球菌感染症の現況と診断基準案の提示. 感染症学雑誌 72:258-265, 1998

• 3) Stevens DL:Invasive group A streptococcus infections. Clin Infect Dis 14:2-11, 1992
  pubmed

• 4) 目黒英典:A群レンサ球菌迅速診断キットの有用性. 小児科臨床 50:593-597, 1997
  Medical*Online

P.57 掲載の参考文献

• 1) 松本慶蔵:抗インフルエンザ薬の有効性と新しく検討されつつある新薬. 化学療法の領域 23:1907-1914, 2007

• ○ 平松直樹:C型慢性肝炎の抗ウイルス療法.3.C型慢性肝炎に対する抗ウイルス療法の新たな展開-Peg-IFN/ribavirin併用療法と新規抗ウイルス療法-. 日本内科学会雑誌 97:75-81, 2008

• ○ 矢崎博久, 岡慎一・:後天性免疫不全症候群 (AIDS). 日本臨牀増刊号, 新感染症学下巻:247-250, 2007

P.59 掲載の参考文献

• ○ 光線過敏症 改訂第3版, 佐藤吉昭監修, 市橋正光, 堀尾武編集, 金原出版, 東京, 2002

• ○ 松尾幸朗編集企画:光線過敏症診断治療マニュアル. Monthly Book Dermatology 21:9-18, 1999

• ○ 一口に光線過敏症というけれど. Visual Dermatology 5月号, 上出良一責任編集, 秀潤社, 東京, 2003

P.62 掲載の参考文献

• 1) UNAIDS/WHO:2007 AIDS Epidemic Update (http://www.unaids.org/en/KnowledgeCentre/HIV-Data/EpiUpdate/EpiUpdArchive/2007/)

• 2) 厚生労働省エイズ動向委員会報告, 2008 (http://api-net.jfap.or.jp/mhw/survey/mhw_survey.htm)

• 3) A Working Group of The Office of AIDS Research Advisory Council (OARAC):Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (DHHS), 2008 (http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf)

• 4) HIV 感染症治療研究会:HIV 感染症「治療の手引き」第11版, (http://www.hivjp.org/), 2007

P.65 掲載の参考文献

• ○ 中山一誠:Bacterial Adherence. 感染症 19:1-4, 1989

• ○ 中山一誠:細菌感染症の発症-特に付着と定着について. 化学療法の領域 8:47-56, 1992

• ○ 中山一誠:Bacterial Adherence-その実態と今後の課題「付着定着, 最近の動向」Bacterial Adherence 研究会講演録 11:89-92, 1998

• ○ 中山一誠:Bacterial Adherence & Biofilm の軌跡-過去, 現在, 未来-. Bacterial Adherence & Biofilm 20:25-37, 2007

P.67 掲載の参考文献

• 1) 公文裕巳:バイオフィルム病(2) 尿路感染症. 最新内科学大系プログレス5 感染症, 中山書店, 東京, 1997, pp.199-207

• ○ Costerton JW, Stewart PS, Greenberg EP:Bacterial biofilms:a common cause of persistent infections. Science 284:1318-1322, 1999
  pubmed

• ○ Kobayashi H:Airway biofilms:implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 4:241-253, 2005
  pubmed

• ○ Parsek MR, Greenberg EP:Sociomicrobiology:the connections between quorum sensing and biofilms. Trends in Microbiol 13:27-33, 2005
  pubmed

P.69 掲載の参考文献

• 1) Raymond DP, Pelletier SJ, Crabtree TD et al:Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 29:1101-1108, 2001

• 2) Bennett KM, Scarborough JE, Sharpe M et al:Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J Trauma 63:307-311, 2007

• 3) Warren DK, Hill HA, Merz LR et al:Cycling empirical amtimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 32:2450-2456, 2004

• 4) Sandiumenge A, Diaz E, Rodriguez A et al:Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 57:1197-1204, 2006

P.71 掲載の参考文献

• ○ コンセンサス肝疾患 2007, 岡上武, 小俣政男, 林紀夫ほか編, 日本メディカルセンター, 東京, 2007

• ○ Akuta N, Suzuki F, Kawamura Y et al:Predoctors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79:1686-1695, 2007
  pubmed

P.73 掲載の参考文献

• 1) Simons JN, Leary TP, Dawson GJ et al:Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1:564-569, 1995
  pubmed

• 2) Linnen J, Wages J Jr, Zhang-Keck ZY et al:Molecular cloning and disease association of hepatitis G virus:a transfusion-transmissible agent. Science 271:505-508, 1996
  pubmed

• 3) Erker JC, Simons JN, Muerhoff AS et al:Molecular cloning and characterization of a GB virus C isolate from a patient with non-A-E hepatitis. J Gen Virol 77:2713-2720, 1996

• 4) Alter HJ, Nakatsuji Y, Melpolder J et al:The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 336:747-754, 1997
  pubmed

• 5) Tillmann HL, Heiken H, Knapik-Botor A et al:Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 345:715-724, 2001

P.75 掲載の参考文献

• 1) Peiris JS, Yuen KY, Osterhaus AD et al:The severe acute respiratory syndrome. N Engl J Med 349:2431-2441, 2003
  pubmed

• 2) Peiris JS, Guan Y, Yuen KY:Severe acute respiratory syndrome. Nat Med 10:S88-S97, 2004
  pubmed

P.77 掲載の参考文献

• ○ Nagy G, Kosa S, Takatsy S et al:The use of IgM tests for analysis of the causes of measles vaccine failures:experience gained in an epidemic in Hungary in 1980 and 1981. J Med Virol 13:93-103, 1984

• ○ Pannuti CS, Morello RJ, Moraes JC et al:Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic. Clin Diagn Lab Immunol 11:119-122, 2004

• ○ 岡田晴恵:麻疹 IgG抗体のavidity測定の臨床的意義. IASR 25:74-75, 2004

• ○ Edomonson MB, Addiss DG, McPherson JT et al:Mild measles and secondary vaccine failure during a sustained outbreak in highly vaccinated population. JAMA 263:2467-2471, 1990

P.79 掲載の参考文献

• 1) 押谷仁:高病原性トリインフルエンザと新型インフルエンザ. 保健の科学 49:669-673, 2007

• 2) Oshitani H:Potential benefits and limitations of various strategies to mitigate the impact of an influenza pandemic. J Infect Chemother 12:167-171, 2006
  pubmed

• 3) 押谷仁:新型インフルエンザ出現の時期と出現後の対応. Progress in Medicine 27:2307-2312, 2007
  Medical*Online

• 4) 押谷仁:鳥インフルエンザ (H5N1)感染症の現況と今後. 日本内科学会雑誌 96:1987-1992, 2007

P.81 掲載の参考文献

• 1) Takahashi H, Tokue Y, Kikuchi T et al:Prevalence of community-acquired respiratory tract infections associated with Q fever in Japan. Diagn Microbiol Infect Dis 48:247-252, 2004
  pubmed

• ○ Marrie TJ:Acute Q fever. In:Q fever volume 1 The disease, ed. by TJ Marrie, CRC Press, Boca Raton,1990,pp.125-160

• ○ Maurin M, Raoult D:Q fever. Clin Microbiol Rev 12:518-553,1999
  pubmed

• ○ Watanabe A,Takahashi H:Diagnosis and treatment of Q fever, attempts to clarify current problems in Japan. J Infect Chemother 14:1-7,2008
  pubmed

P.83 掲載の参考文献

• 1) 三鴨廣繁, 田中香お里, 渡邉邦友:性器クラミジア感染症の現況と対策化学療法の領域 21:49-58, 2005

• 2) 日本性感染症学会:性器クラミジア感染症, 性感染症診断・治療ガイドライン 2006, 日本性感染症学会誌 17:40-43, 2006

• ○ 三鴨廣繁, 田中香お里, 渡邉邦友:新しい臨床検査・未来の臨床検査各論 5. 感染症検査クラミジア・トラコマチス/淋菌核酸同時増幅同定検査. 検査と技術 34:1293-1294, 2006

• ○ 三鴨廣繁, 田中香お里, 渡邉邦友:マクロライド系抗菌薬の使い方 6) 産婦人科領域治療学 41:60-64, 2007

P.85 掲載の参考文献

• 1) 三鴨廣繁, 二宮望祥, 玉舎輝彦:難治化する淋菌感染症・咽頭部への淋菌感染. 感染と抗菌薬 5:267-269, 2002

• 2) 松本哲朗:最近の性感染症の動向. 臨床泌尿器科 61:765-771, 2007

• 3) 性感染症診断・治療ガイドライン 2006. 日本性感染症学会誌 17:35-43, 2006

• 4) CDC:Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006:Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections. MMWR 56:332-336, 2007
  pubmed

P.87 掲載の参考文献

• ○ WHO:Amoebiasis. Wkly Epidemiol Rec 72:97-99, 1997

• ○ Diamond LS, Clark CG:A redescription of Entamoeba histolytica Schaudinn, 1903 (Emended Walker, 1911) separating it from Entamoeba dispar Brumpt, 1925. J Eukaryot Microbiol 40:340-344, 1993
  pubmed

• ○ Ralls PW, Barnes PF, Johnson MB et al:Medical treatment of hepatic amebic abscess:rare need of percutaneous drainage. Radiology 165:805-807, 1987
  pubmed

• ○ Ozdogan M, Baykal A, Aran O:Amebic perforation of the colon:rare and frequently fatal complication.

• World J Surg 28:926-929, 2004
  pubmed

P.89 掲載の参考文献

• ○ Yu VL:Serratia marcescens:historical perspective and clinical review. N Engl J Med 300:887-893, 1979
  pubmed

• ○ Russo TA:Serratia infections. Diseases caused by gram-negative enteric bacilli. In:Harrison's Principles of Internal Medicine 16th. Part six. Infectious diseases, ed. by Fauci AS, Kasper DL, Braunwald E et al, McGraw-Hill, New York, 2005, p.884

• ○ Donnenberg MS:Serratia. Enterobacteriaceae. In:Principles and Practice of Infectious Diseases 6th ed, ed. by Mandell GL, Bennett JE, Dolin R, Churchill Livingstone, Philadelphia, 2005, pp. 2579-2580

P.91 掲載の参考文献

• 1) Bone RC, Balk RA, Cerra FB et al:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992
  pubmed

• ○ Sun D, Aikawa N:The natural history of the systemic inflammatory response syndrome and the evaluation of SIRS criteria as a predictor of severity in patients hospitalized through emergency services. Keio J Med 48:28-37, 1999
  pubmed

• ○ 相川直樹:SIRS と敗血症. 集中治療医学, 日本集中治療医学会編, 秀潤社, 東京, 2001, pp. 331-334

• ○ 相川直樹:SIRS・ショック・MODSの歴史的概観クリティカルケアSIRS・ショック・MODS, 相川直樹, 青木克憲編, 医学書院, 東京, 2001, pp. 2-10

• ○ 相川直樹, 藤島清太郎:SIRS, sepsis, 敗血症の病態解明とsepsisに対する新規治療法の開発. 日本臨牀 62:2173-2176, 2004
  Medical*Online

P.93 掲載の参考文献

• ○ 森康子, 山西弘一:ヘルペスウイルス群の種々相とその特徴. 臨牀と研究 82:1439-1442, 2005
  Medical*Online

P.95 掲載の参考文献

• ○ Canton R, Unal S, Farrell DJ:Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients:PROTEKT years 1-5 (1999-2004). Int J Antimicrob Agents 30:546-550, 2007
  pubmed

• ○ Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. M100-S18. Wayne, PA:CLSI; 2008

• ○ Hiramatsu K, Ohama M, Miyajima Y et al:Antimicrobial susceptibilities and analysis of genes related to penicillin or macrolide resistance in Streptococcus pneumoniae. Int J Antimicrob Agents 24:125-129, 2004
  pubmed

P.97 掲載の参考文献

• 1) 荒川宣親:薬剤耐性緑膿菌感染症. 感染症の診断・治療ガイドライン 2004, 日本医師会, 2004, pp. 308-311

• 2) 森兼啓太:全国サーベイランスにみるMDRP発生動向. 感染対策ICTジャーナル 2:39-42, 2007

• 3) Hirakata Y, Yamaguchi T, Nakano M et al:Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis 37:26-32, 2003

• 4) Li J, Nation RL, Turnidge JD et al:Colistin:the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601, 2006
  pubmed

P.99 掲載の参考文献

• ○ 竹田美文, 村田三紗子, 本田雅敬:腸管出血性大腸菌 (Vero 毒素産生性大腸菌) による出血性大腸炎と溶血性尿毒症症候群の臨床. 日本医師会雑誌 107:1689-1694, 1992

• ○ 泉谷秀昌, 渡辺治雄:腸管出血性大腸菌 (EHEC/ VTEC/STEC) における病原因子の分子生物学的研究の進歩. 日本臨牀 55:131-135, 1997

P.101 掲載の参考文献

• ○ Okamoto H, Nishizawa T, Kato N et al:Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatol Res 10:1-16, 1998

• ○ Mushahwar IK:Recently discovered blood-borne viruses:are they hepatitis viruses or merely endosymbionts? J Med Virol 62:399-404, 2000

• ○ Kanda T, Yokosuka O, Ikeuchi T et al:The role of TT virus infection in acute viral hepatitis. Hepatology 29:1905-1908, 1999
  pubmed

• ○ Lefrere JJ, Roudot-Thoraval F, Lefrere F et al:Natural history of the TT virus infection through follow-up of TTV DNA-positive multiple-transfused patients. Blood 95:347-351, 2000

P.103 掲載の参考文献

• ○ Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus Abdel-GhafarAN, Chotpitayasunondh T et al:Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358:261-273, 2008

• ○ World Health Organization Regional Office for the Western Pacific:Avian influenza, including influenza A (H5N1), in humans:WHO interim infection control guideline for health care facilities. Date of most recent amendment:10 May 2007. http://www.who.int/csr/resources/publications/AI_Inf_Control_Guide_10May2007.pdf

• ○ Schunemann HJ, Hill SR, Kakad M et al:WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7:21-31, 2007
  pubmed

P.105 掲載の参考文献

• ○ Tashiro T, Nagai H, Kamberi P et al:Disseminated Trichosporon beigelii infection in patients with malignant diseases:immunohistochemical study and review. Eur J Clin Microbiol Infect Dis 13:218-224, 1994
  pubmed

• ○ 杉田隆:日和見感染症および夏型過敏性肺炎の原因菌種としてのTrichosporon asahiiの多様性解明. 日本医真菌学会雑誌 44:7-12, 2003

• ○ Giremenia C, Pagano L, Martino B et al:Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies:a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 43:1818-1828, 2005

• ○ 時松一成, 門田淳一:新興深在性真菌症-トリコスポロン症の臨床-. 感染症学雑誌 80:196-202, 2006

P.107 掲載の参考文献

• ○ Thomas CF Jr, Limper AH:Pneumocystis pneumonia. N Engl J Med:350, 2487-2498, 2004
  pubmed

• ○ Green H, Paul M, Vital L et al:Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev:CD005590, 2007

• ○ Sepkowitz KA:Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 34:1098-1107, 2002
  pubmed

P.109 掲載の参考文献

• 1) 三田村敬子, 菅谷憲夫, 韮沢真理ほか:小児のA型およびB型インフルエンザに対するoseltamivirの効果. 感染症学雑誌 76:946-952, 2002

• 2) Sugaya N, Mitamura K, Yamazaki M et al:Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 44:197-202, 2007
  pubmed

• 3) 柏木征三郎, 工藤翔二, 渡辺彰ほか:リン酸オセルタミビルのインフルエンザ発症抑制効果に関する検討プラセボを対照とした第田相二重盲検並行群間比較試験成績. 感染症学雑誌 74:1062-1076, 2000

• 4) 菅谷憲夫:10代のインフルエンザ患者の治療はどうすべきか oseltamivirと異常行動, 転落事故. 日本医事新報 4360:64-68, 2007
  Medical*Online

• 5) Fuke C, Ihama Y, Miyazaki T:Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu(E). Leg Med (Tokyo) 10:83-87, 2008

P.111 掲載の参考文献

• 1) Arroliga AC, Ghamra ZW, Perez Trepichio A et al:Incidence of ARDS in an adult population of northeast Ohio. Chest 121:1972-1976, 2002

• 2) Bersten AD, Edibam C, Hunt T et al:Incidence and mortarity of acute lung injury and the respiratory distress syndrome in three Australian States. Am J Respir Crit Care Med 165:443-448, 2002

• 3) 多治見公高, 武澤純, 氏家良人ほか:日本呼吸療法医学会, 急性呼吸不全実態調査委員会報告書. 人工呼吸 16:33-42, 1999

• 4) Bernard GR, Vincent JL, Laterre PF et al:Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001
  pubmed

P.114 掲載の参考文献

• ○ バンコマイシン耐性腸球菌 (VRE) 感染症ハンドブック, 松本哲朗編, 医薬ジャーナル社, 大阪, 2004

• ○ バンコマイシン耐性菌戦略Q&A, 医薬ジャーナル社, 公文裕巳編, 大阪, 2001

P.117 掲載の参考文献

• 1) Costerton JW, Stewart PS, Greenberg EP:Bacterial biofilms:a common cause of persistent infections. Science 284:1318-1322, 1999
  pubmed

• ○ 王宝禮:くすりが活きる歯周病サイエンス, デンタルダイヤモンド社, 東京, 2007

• ○ 朝波惣一郎, 王宝禮:薬'08/'09 歯科疾患名から治療薬と処方例がすぐわかる本, クインテッセンス出版, 東京, 2008

• ○ Tamura A, Ara T, Imamura Y et al:The effects of antibiotics on in vitro biofilm model of periodontal disease. Eur J Med Res 13:1-7, 2008

P.118 掲載の参考文献

• ○ 日本結核病学会非定型抗酸菌症対策委員会:肺非結核性抗酸菌症診断に関する見解-2003 年. 結核 78:569-572, 2003

• ○ ATS Mycobacterial Diseases Subcommittee;American Thoracic Society;Infectious Disease Society of America:An official ATS/IDSA statement:diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367-416, 2007
  pubmed

P.119 掲載の参考文献

• ○ 坂谷光則,倉島篤行,佐藤滋樹ほか:座談会「肺非結核性抗酸菌症の診断と治療」.呼吸24:106-117,2007

P.123 掲載の参考文献

• 1) Fang L, Meyers C, Budgeon LR et al:Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 347:28-35, 2006
  pubmed

• 2) de Villiers EM, Fauquet C, Broker TR et al:Classification of papillomaviruses. Virology 324:17-27, 2004
  pubmed

• 3) 刈谷方俊, 藤井信吾:子宮頸癌発症機構における Human papillomavirus(HPV)の役割と抗HPVワクチン療法の開発. ウイルス 52:287-293, 2002

• 4) Bilu D, Sauder DN:Imiquimod:modes of action. Br J Dermatol 149:5-8, 2003
  pubmed

• 5) Crosbie EJ, Kitchener HC:Cervarix(R)-a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16-and 18-associated cervical cancer. Expert Opin Biol Ther 7:391-396, 2007

• 6) Joura EA, Leodolter S, Hernandez-Avila M et al:Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions:a combined analysis of three randomised clinical trials. Lancet 369:1693-1702, 2007
  pubmed

• 7) FUTURE II Study Group:Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927, 2007

P.125 掲載の参考文献

• ○ 要藤裕孝, 工藤亨, 長谷山圭司ほか:バキュロウイルス発現抗原を用いたEIAによるヒトパルボウイルスB19抗体の測定. 感染症学雑誌 69:1135-1140, 1995

• ○ Yoto Y, Kudoh T, Haseyama K et al:Human parvovirus B19 infection associated with acute hepatitis. Lancet 347:868-869, 1996
  pubmed

• ○ Qiu J, Yoto Y, Tullis G et al:Parvovirus RNA processing strategies. In:Parvoviruses, ed. by Kerr JR, Cotmore SF, Bloom ME et al, Hodder Arnold Publisher, London, 2006, pp. 253-274

• ○ 要藤裕孝:Papular-purpuric gloves and socks syndrome. こどもの感染症の診かた 7:13, 2007

P.129 掲載の参考文献

• 1) Clinical and Laboratory Standards Institute:Performance Standards for Antimicrobial Susceptibility Testing, Eighteenth Informational Supplement (M100-S18). Wayne, Pennsylvania, USA, 2008

• 2) 抗菌薬感受性測定法検討委員会報告 (1992年):呼吸器感染症および敗血症におけるブレイクポイント. Chemotherapy 42:905-914, 1994

• 3) 抗菌薬感受性測定法検討委員会報告 (1997年):尿路感染症におけるブレイクポイント. 日本化学療法学会雑誌 45:711-726, 1997

• 4) 抗菌薬感受性測定・臨床評価委員会報告:呼吸器感染症および敗血症におけるブレイクポイント:新規抗菌薬の追加 (2005年). 日本化学療法学会雑誌 53:557-559, 2005

P.131 掲載の参考文献

• ○ 小林潤:糞線虫症. G.I. Research 14:342-349, 2006
  Medical*Online

• ○ 城間祥行,喜友名進:第2章 臨床, 日本における糞線虫と糞線虫症, 佐藤良也, 城間祥行編,九州大学出版会,福岡, 1997, pp.29-53

• ○ Zaha O, Hirata T, Uchima N et al:Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother 10:348-351,2004
  pubmed

P.133 掲載の参考文献

• 1) Hotomi M, Fujihara K, Billal DS et al:Genetic characteristics and clonal dissemination of β-lactamase-negative ampicillin resistant Haemophilus influenzae isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother 51:3969-3976, 2007

• ○ Hotomi M, Sakai A, Fujihara K et al:Antimicrobial resistance in Haemophilus influenzae isolated from the nasopharynx among Japanese children with acute otitis media. Acta Otolaryngol 126:130-137, 2006

• ○ Sakai A, Hotomi M, Billal DS et al:Evaluation of mutations in penicillin binding protein-3 gene of non-typeable Haemophilus influenzae isolated from the nasopharynx of children with acute otitis media. Acta Otolaryngol 125:180-183, 2005
  pubmed

• ○ Ubukata K, Shibasaki Y, Yamamoto K et al:Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 45:1693-1699, 2001

P.135 掲載の参考文献

• 1) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter Pylori感染の診断と治療のガイドライン2003年改訂版. 日本ヘリコバクター学会誌 4:2-7, 2003
  Medical*Online

• ○ Marshall BJ:Helicobacter pylori. Am J Gastroenterol 89:S116-S128, 1994
  pubmed

• ○ Asaka M, Satoh K, Sugano K et al:Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6:177-186, 2001
  pubmed

• ○ Malfertheiner P, Leodolter A, Peitz U:Cure of Helicobacter pylori-associated ulcer disease through eradication. Baillieres Best Pract Res Clin Gastroenterol 14:119-132, 2000
  pubmed

P.138 掲載の参考文献

• 1) 小島俊行:母子感染の特徴・母子感染の予防. 研修ノートNo. 70「妊娠と感染症」, 日本産婦人科医会研修委員会編, 日本産婦人科医会, 2004, pp. 6-9

P.141 掲載の参考文献

• ○ Hirsch HH:BK virus:opportunity makes a pathogen. Clin Infect Dis 41:354-360, 2005
  pubmed

• ○ 余郷嘉明:進行性多巣性白質脳症. 2) PML型JCウイルスの起源 (適応説) . スローウイルス感染とプリオン, 山内一也, 立石潤監修, 近代出版, 東京, 1995, pp. 124-133

• ○ 村山繁雄:進行性多巣性白質脳症. 日本内科学会雑誌 95:1274-1278, 2006

P.143 掲載の参考文献

• ○ de la Torre JC:Molecular biology of Borna disease virus:prototype of a new group of animal viruses. J Virol 68:7669-7675, 1994
  pubmed

• ○ Nakamura Y, Takahashi H, Shoya Y et al:Isolation of Borna disease virus from human brain tissue. J Virol 74:4601-4611, 2000

• ○ Ikuta K, Ibrahim MS, Kobayashi T et al:Borna disease virus and infection in humans. Front Biosci 7:d470-d495, 2002
  pubmed

• ○ Kamitani W, Ono E, Yoshino S et al:Glial expression of Borna disease virus phosphoprotein induces behavioral and neurological abnormalities in transgenic mice. Proc Natl Acad Sci USA 100:8969-8974, 2003
  pubmed

• ○ 朝長啓造:細胞核とRNAウイルス ボルナウイルスの核輸送と持続感染のメカニズム. 蛋白質・核酸・酵素 52:1168-1174, 2007

P.145 掲載の参考文献

• 1) Suzuki S, Yamazaki T, Narita M et al:Clinical evaluation of macrolide-resistant Mycoplsma pneumoniae. Antimicrob Agents Chemother 50:709-712, 2006

• ○ 国立感染症研究所 感染症情報センターホームページ http://idsc.nih.go.jp/idwr/kanja/weeklygraph/18myco.html

• ○ 玉置尚司:マイコプラズマ. 小児感染症学, 岡部信彦編, 診断と治療社, 東京, 2007, pp. 493-498

• ○ 成田光生:肺炎マイコプラズマ感染症. 日常診療に役立つ小児感染症マニュァル 2007 改訂第2版, 日本小児感染症学会編, 東京医学社, 東京, 2007, pp. 109-115

• ○ 小児呼吸器感染症診療ガイドライン 2007, 上原すゞ子, 砂川慶介監修, 協和企画, 東京, 2007

P.147 掲載の参考文献

• 1) 前田明彦, 佐藤哲也, 石浦嘉人ほか:この10年間で解明されたこと. 慢性活動性EBウイルス感染症臨床とウイルス 34:123-132, 2006

• 2) Kimura H, Morishima T, Kanegane H et al:Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187:527-533, 2003
  pubmed

• 3) Kimura H, Hoshino Y, Kanegane H et al:Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98:280-286, 2001
  pubmed

• 4) Okano M, Kawa K, Kimura H et al:Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80:64-69, 2005
  pubmed

• 5) EB ウイルス感染症研究会:慢性活動性EBウイルス感染症 (CAEBV) 診断指針 (http://www.ebken.org/indicator/CAEBV0113.pdf)

P.149 掲載の参考文献

• 1) Bergstrom CT, Lo M, Lipsitch M:Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 101:13285-13290, 2004

• 2) Martinez JA, Nicolas JM, Marco F et al:Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 34:329-336, 2006
  pubmed

• 3) 竹末芳生, 大毛宏喜:抗菌薬ミキシング. Progress in Medicine 25:2317-2322, 2005
  Medical*Online

• 4) Takesue Y, Ohge H, Sakashita M et al:Effect of antibiotic heterogeneity on the development of infections with antibiotic-resistant gram-negative organisms in a non-intensive care unit surgical ward. World J Surg 30:1269-1276, 2006

P.151 掲載の参考文献

• 1) Bocchini CE, Hulten KG, Mason EO Jr et al:Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 117:433-440, 2006
  pubmed

• 2) CDC:Guidelines for environmental infection control in health-care facilities. http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Enviro_guide_03.pdf

• 3) CDC:Methicillin-resistant Staphylococcus aureus. http://wwv.cdc.gov/ncidod/dhqp/ar_mrsa_healthcareFS.html

• 4) Muto CA, Jernigan JA, Ostrowsky BE et al:SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 24:362-386, 2003
  pubmed

P.153 掲載の参考文献

• ○ 斧康雄:易感染性をきたす生体防御機構の欠損. 感染症学雑誌 80:475-479, 2006

• ○ Donnelly Jp, De Pauw BE:Infections in the immuno-compromised hosts:General principles. In:Principles and Practice of Infectious Diseases 6th ed, ed. by Mandell GL, Bennett JE, Dolin R, Churchill Livingstone, Philadelphia, 2004, pp. 3421-3432

P.155 掲載の参考文献

• ○ Applied Pharmacokinetics & Pharmacodynamics. In:Principles of Therapeutic Drug Monitoring 4th ed, ed. by Burton ME, Shaw LM, Schentag JJ et al, Lippincott Williams & Wilkins, Philadelphia, 2005

• ○ 今日の治療指針 2008年版, 山口徹, 北原光夫, 福井次矢編, 医学書院, 東京, 2008, pp. 1219-1231

P.157 掲載の参考文献

• 1) 高松純樹:第49回日本臨床血液学会合同総会 教育講演26:輸血とウイルス感染, 日本臨床血液学会誌 48:1422-1427, 2007

• ○ 百瀬俊哉:WS1 輸血感染症対策 1. 輸血感染症の現状, 第55回日本輸血・細胞治療学会総会講演, 日本輸血細胞治療学会誌 53:199, 2007

• ○ 半田誠:輸血と感染症, 日本医師会雑誌 127:363-366, 2002

• ○ Stramer SL:Current risks of transfusion-transmitted agents:a review. Arch Pathol. Lab Med 131:702-707, 2007
  pubmed

P.159 掲載の参考文献

• 1) Fraser DW, Tsai TR, Orenstein W et al:Legionnaires' disease:description of an epidemic of pneumonia. N Engl J Med 297:1189-1197, 1977
  pubmed

• 2) Higa F, Edelstein PH:Potential virulence role of the Legionella pneumophila ptsP ortholog. Infect Immun 69:4782-4789, 2001
  pubmed

• 3) 新版レジオネラ症防止指針, 厚生省生活衛生局企画課 監修,(財)ビル管理教育センター, 東京, 1999

• ○ 山口惠三, 舘田一博, 石井良和ほか:Legionella肺炎の診断法と臨床的特徴に関する検討. 感染症学雑誌 71:634-643, 1997

• ○ レジオネラ感染症ハンギブック, 斎藤厚編, 日本医事新報社, 東京, 2007

基礎編

P.163 掲載の参考文献

• 1) Ramaswamy S, Musser JM:Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis:1998 update. Int J Tuberc Lung Dis 79:3-29, 1998

• ○ TB-Alliance:Rifampin. Handbook of Anti-Tuberculosis Agents. Tuberculosis (ELSEVIER) 88:151-154, 2008

• ○ Huitric E, Werngren J, Jureen P et al:Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 50:2860-2862, 2006
  pubmed

• ○ Honore N, Cole S:Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 37:414-418, 1993
  pubmed

P.166 掲載の参考文献

• 1) 近真理奈, 倉園貴至, 大島まり子ほか:下痢症患者から分離されたcefotaxime耐性志賀毒素産生性大腸菌O26:H11について. 感染症学雑誌 79:161-168, 2005

• 2) 森田耕司, 渡辺登, 金森政人ほか:志賀毒素産生大腸菌O26:H11株が保有する高頻度伝達性プラスミドに認めた新規ホスホマイシン耐性遺伝子. 感染症学雑誌 81 (臨時増刊号):221, 2007

• ○ Philippon A, Arlet G, Jacoby GA:Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 46:1-11, 2002

• ○ Grohmann E, Muth G, Espinosa M:Conjugative plasmid transfer in gram-positive bacteria. Microbiol Mol Biol Rev 67:277-301, 2003
  pubmed

• ○ Nordmann P, Poirel L:Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 56:463-469, 2005
  pubmed

P.169 掲載の参考文献

• 1) 渡辺秀裕, 梛野健司, 武田英紀ほか:マクロライド薬の側鎖の影響分子呼吸器病 1:395-403, 1997

• ○ Ryder C, Byrd M, Wozniak DJ:Role of polysaccharides in Pseudomonas aeruginosa biofilm development. Curr Opin Microbiol 10:644-648, 2007
  pubmed

• ○ Kobayashi H:Airway biofilms:implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 4:241-253, 2005
  pubmed

• ○ Wozniak DJ, Keyser R:Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125 (2 Suppl):62S-69S, 2004

P.171 掲載の参考文献

• ○ MacMicking J, Xie QW, Nathan C:Nitric oxide and macrophage function. Annu Rev Immunol 15:323-350, 1997
  pubmed

• ○ Zaki MH, Akuta T, Akaike T:Nitric oxide-induced nitrative stress involved in microbial pathogenesis. J Pharmacol Sci 98:117-129, 2005
  pubmed

• ○ Akaike T, Maeda H:Nitric oxide and virus infection. Immunology 101:300-308, 2000
  pubmed

P.174 掲載の参考文献

• 1) Vandegraaff N, Engelman A:Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev Mol Med 9:1-19, 2007
  pubmed

• ○ Craigie R:HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 276:23213-23216, 2001
  pubmed

• ○ De Clercq E:The design of drugs for HIV and HCV. Nat Rev Drug Discov 6:1001-1018, 2007
  pubmed

P.177 掲載の参考文献

• 1) Message SD, Johnston SL:The immunology of virus infection in asthma. Eur Respir J 18:1013-1025, 2001
  pubmed

• ○ Yewdell Jw, Bennink JR:Immune response to viruses. In:Clinical Virology, ed. by Richman DD, whitley RJ, Hayden FG, Churchill Living Stone, New York, 1997, pp. 271-306

• ○ Whitton JL:Oldstone MBA. Immune response to viruses. In:Field's Virology 3rd ed, ed. by Fields BN, Knipe DM, Howley PM, Lippincott Raven, Philadelphia, 1996, pp. 345-374

• ○ Hayden FG, Fritz R, Lobo MC et al:Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 101:643-649, 1998
  pubmed

P.179 掲載の参考文献

• 1) 柳雄介 ウイルス受容体. 感染症 34:133-140, 2004

• ○ Marsh M, Helenius A:Virus entry:open sesame. Cell 124:729-740, 2006
  pubmed

• ○ Helenius A:Virus entry and uncoating. In:Fields Virology, 5th, ed. by DM Knipe et al, Lippincott Williams & Wilkins, Philadelphia, 2007, pp. 99-118

P.181 掲載の参考文献

• ○ McLaughlin-Drubin ME, Munger K:Viruses associated with human cancer. Biochim Biophys, Acta 1782:127-150, 2008
  pubmed

P.184 掲載の参考文献

• 1) 柳雄介:ウイルス感染の機構. 戸田新細菌学第32版, 吉田真一, 柳雄介編, 南山堂, 東京, 2002, p. 257

• 2) Lamb RA, Kolakofsky D:Paramyxoviridae:The viruses and Their Replication. In:Fields Virology 4th ed, ed. by Knipe DM, Howley PM, Griffin DE et al, Lippincott Williams & Wilkins, Philadelphia, 2001, p. 1323

• 3) Wright PF, Webster RG:Orthomyxoviruses. In:Fields Virology 4th ed, ed. by Knipe DM, Howley PM, Griffin DE et al, Lippincott Williams & Wilkins, Philadelphia, 2001, p. 1544

• 4) Lamb RA, Parks GD:Paramyxoviridae:The viruses and Their Replication. In:Fields Virology 5th ed, ed. by Knipe DM, Howley PM, Griffin DE et al, Lippincott Williams & Wilkins, Philadelphia, 2007, p. 1473

• 5) Wright PF, Neumann G, Kawaoka K:Orthomyxoviruses. In:. Fields Virology 5th ed, ed. by Knipe DM, Howley PM, Griffin DE et al, Lippincott Williams & Wilkins, Philadelphia, 2007, p. 171

• ○ Yanagi Y, Takeda M, Ohno S et al:Measles virus receptors and tropism. Jpn J Infect Dis 59:1-5, 2006
  pubmed

• ○ 小池智:ポリオウイルスの神経トロピズム. 蛋白質・核酸・酵素 52:1231-1236, 2007

• ○ 八田正人, 河岡義裕:インフルエンザウイルスの病原決定因子. 蛋白質・核酸・酵素 52:1237-1241, 2007

P.187 掲載の参考文献

• ○ Nienhuis AW, Dunbar CE, Sorrentino BP:Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13:1031-1049, 2006
  pubmed

• ○ McConnell MJ, Imperiale MJ:Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 15:1022-1033, 2004
  pubmed

• ○ Wu Z, Asokan A, Samulski RJ:Adeno-associated virus serotypes:vector toolkit for human gene therapy. Mol Ther 14:316-327, 2006
  pubmed

P.189 掲載の参考文献

• ○ Gershoni JM, Roitburd-Berman A, Siman-Tov DD et al:Epitope mapping:the first step in developing epitope-based vaccines. Bio Drugs 21:145-156, 2007

• ○ Hager-Braun C, Tomer KB:Determination of protein-derived epitopes by mass spectrometry. Expert Rev Proteomics 2:745-756, 2005
  pubmed

• ○ Ovsyannikova IG, Johnson KL, Bergen HR 3rd et al:Mass spectrometry and peptide-based vaccine development. Clin Pharmacol Ther 82:644-652, 2007
  pubmed

• ○ Sette A, Peters B:Immune epitope mapping in the post-genomic era:lessons for vaccine development. Curr Opin Immunol 19:106-110, 2007

P.191 掲載の参考文献

• 1) 三宅健介:感染防御システムにおける自然免疫の役割. 細胞工学 25:734-735, 2006

• ○ Dauphinee SM, Karsan A:Lipopolysaccharide signaling in endothelial cells. Lab Invest 86:9-22, 2006
  pubmed

• ○ Palsson-McDermott EM, O'Neill LA:Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 113:153-162, 2004
  pubmed

• ○ Miyake K:Endotoxin recognition molecules MD-2 and toll-like receptor 4 as potential targets for therapeutic intervention of endotoxin shock. Curr Drug Targets Inflamm Allergy 3:291-297, 2004
  pubmed

P.193 掲載の参考文献

• 1) Boshoff C, Weiss RA:Kaposi's sarcoma-associated herpesvirus. Adv Cancer Res 75:57-86, 1998
  pubmed

• ○ Hengge UR, Ruzicka T, Tyring SK et al:Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1:epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2:281-292, 2002
  pubmed

• ○ Hengge UR, Ruzicka T, Tyring SK et al:Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2:pathogenesis, Castleman's disease, and pleural effusion lymphoma Lancet Infect Dis 2:344-352, 2002
  pubmed

• ○ Elgui de Oliveira D:DNA viruses in human cancer:an integrated overview on fundamental mechanisms of viral carcinogenesis. Cancer Lett 247:182-196, 2007
  pubmed

• ○ Staudt MR, Dittmer DP:The Rta/Orf50 transactivator proteins of the γ-herpesviridae. Curr Top Microbiol Immunol 312:71-100, 2007

P.195 掲載の参考文献

• ○ 浅野茂隆:G-CSF. サイトカイン・ケモカインのすべて, 日本医学館, 東京, 2004, pp. 305-314

• ○ Dale DC:Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62:1-15, 2002
  pubmed

• ○ Dale DC, Liles WC, Summer WR et al:Review:granulocyte colony-stimulating factor--role and relationships in infectious diseases. J Infect Dis 172:1061-1075, 1995
  pubmed

P.197 掲載の参考文献

• 1) Clinical and Laboratory Standards Institute:Performance Standards for Antimicrobial Susceptibility Testing, Seventeenth Information Supplement M100-S17. Wayne (PA), 2007

• ○ Canton R, Coque TM:The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9:466-475, 2006

• ○ Paterson DL:Resistance in gram-negative bacteria:enterobacteriaceae. Am J Med 119:S20-S28; discussion S62-S70, 2006

• ○ Paterson DL, Bonomo RA:Extended-spectrum β-lactamases:a clinical update. Clin Microbiol Rev 18:657-686, 2005

• ○ Ramphal R, Ambrose PG:Extended-spectrum β-lactamases and clinical outcomes:current data. Clin Infect Dis 42:S164-S172, 2006

P.199 掲載の参考文献

• 1) Kacian DL:Methods for assaying reverse transcriptase. In:Method in virology volume VI ed. by Maramorosch K, Koprowski H, Academic Press, New York, 1977, pp. 143-184

• ○ Kohlstaedt LA, Wang J, Friedman JM et al:Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790, 1992
  pubmed

P.201 掲載の参考文献

• 1) 東匡伸:医科ウイルス学, 大里外誉郎編, 南江堂, 東京, 2000

• 2) 小澤敬也:ウイルスベクターと遺伝子治療. KEY-WORD 感染症 第2版, 先端医学社, 東京, 2008, pp. 186-187

• ○ Holland JJ:Defective viral genomes. In:Fields Virology 2nd ed, ed. by Fields BN, Knipe DM, Raven Press, New York, 1990, pp. 151-165

• ○ Roux L, Simon AE, Holland JJ:Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Adv Virus Res 40:181-211, 1991
  pubmed

P.203 掲載の参考文献

• ○ Reid AH, Taubenberger JK:The origin of the 1918 pandemic influenza virus:a continuing enigma. J Gen Virol 84:2285-2292, 2003
  pubmed

• ○ Finkelstein DB, Mukatira S, Mehta PK et al:Persistent host markers in pandemic and H5NI influenza viruses. J Virol 81:10292-10299, 2007

• ○ Wright PF, Neumann G, Kawaoka Y:Orthomyxoviruses. In:Fields Virolog 5th ed, ed. by Knipe DM, Howley PM, Griffin DE et al, Lippincott Williams & Wilkins, Philadelphia, 2007, pp. 1691-1740

P.205 掲載の参考文献

• ○ Girard G, Bloemberg GV:Central role of quorum sensing in regulating the production of pathogenicity factors in Pseudomonas aeruginosa. Futare Microbiol 3:97-106, 2008
  pubmed

• ○ Hughes DT, Sperandio V:Inter-kingdom signalling:communication between bacteria and their hosts. Nat Rev Microbiol 6:111-120, 2008
  pubmed

• ○ Waters CM, Bassler BL:Quorum sensing:cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol 21:319-346, 2005
  pubmed

• ○ Tateda K, Ishii Y, Kimura S et al:Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides:a promising strategy or an oriental mystery? J Infect Chemother 13:357-367, 2007
  pubmed

P.207 掲載の参考文献

• ○ 中島泉:細胞傷害性T細胞. KEY WORD 1997-'98, 先端医学社, 東京, 1996, pp. 82-83

• ○ Fearon DT:The expansion and maintenance of antigen-selected CD8+T cell clones. Adv Immunol 96:103-139, 2007
  pubmed

P.209 掲載の参考文献

• ○ Adinolfi LE, Bonventre PF:Enhanced phagocytosis, killing, and serum sensitivity of Escherichia coli and Staphylococcus aureus treated with sub-MICs of imipenem. Antimicrob Agents Chemother 32:1012-1018, 1988
  pubmed

• ○ Mandell LA, Afnan M:Mechanisms of interaction among subinhibitory concentrations of antibiotics, human polymorphonuclear neutrophils, and gram-negative bacilli. Antimicrob Agents Chemother 35:1291-1297, 1991
  pubmed

• ○ Gemmell CG, Lorian V:Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence, and susceptibility to immunodefenses:Clinical significance. In:Antibiotics in Laboratory Medicine, ed. by Lorian V, Williams & Wilkins, Baltimore, 1996, pp. 397-452

• ○ Odenholt I:Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 17:1-8, 2001
  pubmed

• ○ Cerca N, Martins S, Pier GB et al:The relationship between inhibition of bacterial adhesion to a solid surface by sub-MICs of antibiotics and subsequent development of a biofilm. Res Microbiol 156:650-655, 2005
  pubmed

• ○ Wojnicz D, Jankowski S:Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains. Int J Antimicrob Agents 29:700-704, 2007
  pubmed

• ○ Tateda K, Ishii Y, Kimura S et al:Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides:a promising strategy or an oriental mystery? J Infect Chemother 13:357-367, 2007
  pubmed

P.212 掲載の参考文献

• 1) 松島綱治:ケモカイン overview. 別冊・医学のあゆみ「サイトカイン-state of arts」, 医歯薬出版, 東京, 2004, p. 171

• ○ Feng Y, Broder CC, Kennedy PE et al:HIV-1 entry cofactor:functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877, 1996

• ○ Deng H, Liu R, Ellmeier W et al:Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666, 1996

• ○ Tiemessen CT, Kuhn L:CC chemokines and protective immunity:insights gained from mother-to-child transmission of HIV. Nat lmmunol 8:219-222, 2007
  pubmed

P.215 掲載の参考文献

• ○ 0gawa M:Mechanisms of the development of organ failure following surgical insult:the 'second' attack theory. Clin Intensive Care 7:34-38, 1996

• ○ 小川道雄:局所の SIRS, 全身の CARS-新しい概念の提唱-. 救急医学 23:1924-1927, 1999

• ○ 0gawa M:From SIRS and CARS to SLIRS and LISIS-New concepts for understanding the development of organ failure after clinical insults. Clin Intensive Care 13:143-146, 2002

• ○ 小川道雄:侵襲に対する生体反応と臓器障害-SIRS・ CARS から SLIRS・LISIS へ-. メジカルセンス, 東京, 2004, pp. 1-188

P.217 掲載の参考文献

• ○ Johnson JR:Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 4:80-128, 1991
  pubmed

• ○ Siitonen A, Martikainen R, Ikaheimo R et al:Virulence-associatcd characteristics of Escherichia coli in urinary tract infection:a statistical analysis with special attention to type 1C fimbriation. Microb Pathog 15:65-75, 1993

• ○ Connell I, Agace W, Klemm P et al:Type 1 fimblial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 93:9827-9832, 1996
  pubmed

• ○ Bergsten G, Wullt B, Schembri MA et al:Do type 1 fimbriae promote inflammation in the human urinary tract? Cell Microbiol 9:1776-1781, 2007

P.219 掲載の参考文献

• 1) Freed EO, Martin MA:HIVs and Their Replication. In:Fields Virology, ed. by Knipe DM, Howley PM et al Lippincott Williams and Wilkins, Philadelphia, 2001, pp. 1971-2042

• 2) Zhou Q, Yik JH:The Yin and Yang of P-TEFb regulation:implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev 70:646-659, 2006
  pubmed

• ○ Peruzzi F:The multiple functions of HIV-1 Tat:proliferation versus apoptosis. Front Biosci 11:708-717, 2006
  pubmed

• ○ Brady J, Kashanchi F:Tat gets the "green" light on transcription initiation. Retrovirology 2:69, 2005.
  pubmed

P.221 掲載の参考文献

• 1) Nollmann M, Crisona NJ, Arimondo PB:Thirty years of Escherichia coli DNA gyrase:from in vivo function to single-molecule mechanism. Biochimie 89:490-499, 2007
  pubmed

• ○ Andriole VT:The quinolones:past, present, and future. Clin Infect Dis 41(Suppl 2):S113-S119, 2005

• ○ Quinolone antimicrobial agents 3rd ed, ed. by Hooper DC, Rubinstein E, ASM press, Washington, D.C., 2003

• ○ ニューキノロン剤の臨床応用. 小林宏行編, 医薬ジャーナル社, 大阪, 2001

P.223 掲載の参考文献

• ○ Komatsuzawa H, Ouhara K, Yamada S et al:Innate defenses against methicillin-resistant Staphylococcus aureus (MRSA) infection. J Pathol 208:249-260, 2006
  pubmed

• ○ Lehrer RI, Ganz T:Antimicrobial peptides in mammalian and insect host defense. Curr Opin Immunol 11:23-27, 1999
  pubmed

• ○ Selsted ME, Quellette AJ:Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551-557, 2005

• ○ Yang D, Biragyn A, Kwak LW et al:Mammalian defensins in immunity:more than just microbicidal. Trends Immunol 23:291-296, 2002
  pubmed

P.225 掲載の参考文献

• 1) Skerker JM, Berg HC:Direct observation of extension and retraction of type IV pili. Proc Natl Acad Sci USA 98:6901-6904, 2001
  pubmed

• 2) Wall D, Kaiser D:Type IV pili and cell motility. Mol Microbiol 32:1-10, 1999
  pubmed

• 3) Comolli JC, Hauser AR, Waite L et al:Pseudomonas aeruginosa gene products PilT and Pil U are required for cytotoxity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 67:3625-3630, 1999

• ○ Burrows LL:Weapons of mass retraction. Mol Microbiol 57:878-888, 2005
  pubmed

P.228 掲載の参考文献

• ○ 岩坂日出男:ストレス蛋白研究の現状と展望. ICC と CCU 30:327-335, 2006

• ○ Quintana FJ, Cohen IR:Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J Immunol 175:2777-2782, 2005
  pubmed

• ○ Henderson B, Allan E, Coates AR:Stress wars:the direct role of host and bacterial molecular chaperones in bacterial infection. Infect Immun 74:3693-3706, 2006
  pubmed

P.231 掲載の参考文献

• ○ Cullen BR:The role of Nef in the replication cycle of the human and simian immunodeficiency viruses. Virology 205:1-6, 1994
  pubmed

• ○ Trono D:HIV accessory proteins:leading roles for the supporting cast. Cell 82:189-192, 1995
  pubmed

• ○ Naghavi MH, Goff SP:Retroviral proteins that interact with the host cell cytoskeleton. Curr Opin Immunol 19:402-407, 2007

• ○ 足立昭夫, 鎌田和弥, 八町和樹ほか:HIV-1の病原性とアクセサリー遺伝子. 蛋白質・核酸・酵素 52:1261-1267, 2007

P.233 掲載の参考文献

• 1) 松本哲哉:細菌のトランスロケーション. 新感染症学 (上巻), 日本臨牀65 (増):73-77, 2007

• ○ Tancrede CH, Andremont AO:Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152:99-103, 1985
  pubmed

• ○ Berg RD, Wommack E, Deitch EA:Immunosuppression and intestinal bacterial overgrowth synergistically promote bacterial translocation. Arch Surg 123:1359-1364, 1988
  pubmed

• ○ 山口惠三, 舘田一博, 朝野和典:白血球減少マウスをモデルとした敗血症の誘因と発症機序にっいての検討 (1) 敗血症の成立に及ぼす抗生剤の影響. 感染症学雑言志 63:195-202, 1989

P.237 掲載の参考文献

• ○ 小野寺節, 山内一也:牛海綿状脳症 (BSE) . 人と動物のプリオン病, 品川森一, 立石潤, 山内一也編, 近代出版, 東京, 2003, pp. 139-163

• ○ Nathanson N, Wilesmith J:Bovine Spongiform Encephalopathy and Related Diseases. In:PRION BIOLOGY AND DISEASES, ed. by Prusiner SB, Cold Spring Harbor Laboratory Press, New York, 1999, pp. 431-463

• ○ Department for Environment Food and Rural Affairs:BSE:Science & research-BSE in cattle (http://www.defra.gov.uk/animalh/bse/science-research/cattle/index.htm)

P.239 掲載の参考文献

• 1) 堀誠治:PK/PD解析からみた効果的かつ安全な抗菌薬適正使用. YAKUGAKU ZASSHI 127:931-937, 2007
  Medical*Online

• 2) Vogelman B, Gudmundsson S, Leggett J et al:Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847, 1988

• 3) Vesga O, Bonnat C, Craig WA:Interscience Conference on Antimicrobial Agents and Chemotherapy 37th, American Society for Microbiology, Washington, DC, 1997

• 4) Drusano GL, Craig WA:Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 9:38-44, 1997
  pubmed

• 5) Drusano G, Labro MT, Cars O et al:Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect 4:S27-S41, 1998
  pubmed

• 6) Andes D, Craig WA:Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother 46:1665-1670, 2002
  pubmed

• 7) Andes D, Craig WA:Understanding pharmacokinetics and pharmacodynamics In:Antibiotic Optimization, ed. by Owens RC, Ambrose PG, Nightingale CH, Marcel Dekker, New York, 2005, pp. 65-88

• 8) 戸塚恭一:PK/PD分析による抗菌薬評価の現状と展望. 月刊薬事 46:2127-2131, 2004
  Medical*Online

• 9) 戸塚恭一:体内動態およびPK/PDに基づいた投与計画. 化学療法の領域 19:523-527, 2003

• 10) 笠井英史, 谷川原祐介:母集団薬物動態パラメータとモンテカルロ・シミュレーションで何ができるか. 化学療法の領域 20:1798-1802, 2004

• 11) Andes D, Craig WA:Understanding pharmacokinetics and pharmacodynamics:application to the antimicrobial formulary decision process. Antibiotic Optimization. In:Concepts and Strategies in Clinical Practice, ed. by Owens RC Jr, Ambrose PG, Nightingale CH, Marcel Dekker, NewYork, 2005, pp. 65-88

• 12) Kuti JL, Nicolau DP:Application of pharmacodynamic principles:from theory to practice. In:Antibiotic Optimization Concepts and Strategies in Clinical Practice, ed. by Owens RC Jr, Ambrose PG, Nightingale CH, Marcel Dekker, NewYork, 2005, pp. 353-381

• 13) Craig WA:Pharmacodynamics of antimicrobials:general concepts and applications. In:Antimicrobial Pharmacodynamics in Theory and Clinical Practice, ed. by Nightingale CH, Ambrose PG, Drusano GL et al, Informa Healthcare USA Inc, New York, 2007, pp. 1-19

• 14) 阿部教行, 小松方:PK/PDを考慮したブレークポイントとTDM. 化学療法の領域 20:1822-1828, 2004

P.243 掲載の参考文献

• 1) Saiki RK, Scharf S, Faloona F et al:Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354, 1985
  pubmed

• 2) 葛島清隆, 森島恒雄:PCR法(ウイルス), KEYWORD 感染症 1997-'98, 先端医学社, 東京, 1996, pp. 134-135

• 3) Barnes WM:PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates Proc Natl Acad Sci USA 91:2216-2220, 1994
  pubmed

P.245 掲載の参考文献

• 1) 松田清治:産婦人科領域のSTD (現状・検査・診断) . 性感染症/HIV感染-その現状と検査・診断・治療. メジカルビュー社, 東京, 2001, pp. 78-87

• 2) 日本性感染症学会:性器クラミジア感染症. 性感染症診断・治療ガイドライン 2006. 日本性感染症学会誌 17:40-43, 2006

• 3) Soderblom T, Blaxhult A, Fredlund H et al:Impact of a genetic variant of Chlamydia trachomatis on national detection rates in Sweden. Euro Surveill 11:1-10, 2006

P.247 掲載の参考文献

• 1) Williams DL:PCR and Diagnosis of Tuberculosis. In:Tuberculosis, ed. by Madkour MM, Springer, Germany, 2004, pp. 199-211

• 2) Talbot EA, Williams DL, Frothingham R:PCR identification of Mycobacterium bovis BCG. J Clin Microbiol 35:566-569, 1997
  pubmed

• ○ 斎藤肇:分離培養. 結核菌検査指針 2007, 日本結核病学会抗酸菌検査法検討委員会編, 財団法人結核予防会出版調査課, 東京, 2007, pp. 31-50

• ○ Takewaki S, Okuzumi K, Ishiko H et al:Genus-specific polymerase chain reaction for the mycobacterial dnaJ gene and species-specific oligonucleotide probes. J Clin Microbiol 31:446-450, 1993
  pubmed

• ○ Maeda S, Kobayashi K:Current topics on classification and nomenclature of bacteria, Classification of Mycobacterium tuberculosis complex on the basis of its genomic structure. Kansenshogaku Zasshi 77:651-653, 2003
  pubmed

• ○ 前田伸司, 小林和夫:感染症結核菌および非結核性抗酸菌. 増刊号「遺伝子検査-診断とリスクファクター」, 臨床検査 51:1507-1510, 2007

P.249 掲載の参考文献

• ○ 特集 感染症診断の迅速化をめざして-感染症検査のPOCTを中心に-. 臨床と微生物 34, 2007

• ○ 満田年宏:感染症診療・感染対策に役立つ臨床微生物検査の基礎知識, 国際医学出版, 東京, 2004

P.251 掲載の参考文献

• 1) Honda J, Yonemitsu J, Kitajima H et al:Clinical utility of capillary polymerase chain reaction for diagnosis of cytomegalovirus pneumonia. Scand J Infect Dis 33:702-705, 2001
  pubmed

• ○ Meijer E, Boland GJ, Verdonck LF:Prevention of Cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 16:647-657, 2003
  pubmed

• ○ 本田順一:日和見感染症 サイトメガロウイルス, カリニを中心に. 呼吸 21:925-929, 2002
  Medical*Online

P.253 掲載の参考文献

• ○ 河崎昌子:遺伝学的同定法. 病原性真菌ハンドブック, 宮治誠編, 医薬ジャーナル社, 大阪, 2007, pp. 69-73

• ○ 槇村浩一:真菌症の遺伝子診断法. 病原性真菌ハンドブック, 宮治誠編, 医薬ジャーナル社, 大阪, 2007, pp. 100-104

• ○ 山口英世:補助診断法 (2):遺伝子診断法. 病原真菌と真菌症改訂4版. 南山堂, 東京, 2007, pp. 102-107

• ○ Hayden RT, Isotalo PA Parrett T et al:In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 12:21-26, 2003
  pubmed

P.255 掲載の参考文献

• 1) Xiang-Qi Mu, Bullitt E:Structure and assembly of Ppili:A protruding hinge region used for assembly of a bacterial adhesion filament. PNAS 103:9861-9866, 2006
  pubmed

• ○ Mobley HLT, Warren JW:Urinary tract infections, Molecular Pathogenesis and Clinical Management, ASM Press, Washington, D.C., 1995

• ○ Godaly G, Svanborg C:Urinary tract infections revisited. Kidney Int 71:721-723, 2007
  pubmed

P.257 掲載の参考文献

• 1) Kobayashi O:Clinical role of autoantibody against bactericidal/permeability-increasing protein in chronic airway infection. J Infect Chemother 4:83-93, 1998

• 2) Ohtami S, Kobayashi O, Ohtami H:Analysis of intractable factors in chronic airway infections:role of the autoimmunity induced by BPI-ANCA. J Infect Chemother 7:228-238, 2001

• 3) Zhao MH, Jayne DR, Ardiles LG et al:Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QIM 89:259-265, 1996

• 4) Cooper T, Savige J, Nassis L et al:Clinical associations and characterization of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing Protein and azurocidin. Rheumatol Int 19:129-136, 2000

• 5) Manolova I, Dancheva M, Halacheva K:Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus:prevalence, antigen specificity, and clinical associations. Rheumatol Int 20:197-204, 2001
  pubmed

• 6) Schultz H:From infection to autoimmunity:a new model for induction of ANCA against the bactericidal/permeability-increasing Protein (BPI). Autoimmun Rev 6:223-227, 2007
  pubmed

• 7) Schultz H, Weiss J, Carroll SF et al:The endotoxin-binding bactericidal/permeability-increasing protein (BPI):a target antigen of autoantibodies. J Leukoc Biol 69:505-512, 2001
  pubmed

• 8) Mahadeva R, Dunn AC, Westerbeek RC et al:Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 117:561-567, 1999
  pubmed

P.259 掲載の参考文献

• ○ クロイッフェルト・ヤコブ病. スローウイルス感染とプリオン, 山内一也, 立石潤監修, 近代出版, 東京, 1995

• ○ 立石潤:PNE モノグラフプリオンとプリオン病, 共立出版, 東京, 1998

• ○ 日詰正樹, 篠原もえ子, 八谷如美ほか:プリオン病. 日本臨牀 65:1373-1459, 2007

P.262 掲載の参考文献

• 1) 木戸博:プロテアーゼ阻害薬と感染症. KEY WORD 感染症1997-'98, 先端医学社, 東京, 1996, pp. 158-159

• 2) 吉澤定子:レトロウイルスとエイズ. イラストレイテッド微生物学 第2版, 山口惠三, 松本哲哉監訳, 丸善, 東京, 2008, pp. 319-332

• 3) 潟永博之:抗HIV薬の臨床. 日本薬理学雑誌 130:152-156, 2007
  Medical*Online

• 4) DHHS:Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-January 29, 2008 http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf

• 5) Moyle G:Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 45:S19-S26, 2007
  pubmed

• 6) Vlahakis SR, Bennett SA, Whitehead SN et al:HIV protease inhibitors modulate apoptosis signaling in vitro and vivo. Apoptosis 12:969-977, 2007
  pubmed

P.265 掲載の参考文献

• 1) 満田年宏:感染対策のための分子疫学入門パルスフィールドゲル電気泳動法を中心に. メディカ出版, 大阪, 2002

• ○ Lee W. Riley:Molecular Epidemiology of Infectious Diseases. Principles and Practices, American Society for Microbiology, Washington, D.C., 2004

P.267 掲載の参考文献

• 1) 井上松久, 岡本了一:作用機序. セフェム系抗生物質, 松本慶三編, 医薬ジャーナル社, 大阪, 1991, pp. 36-41

• ○ Spratt BG, Cromie KD:Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis 10:699-711, 1988
  pubmed

• ○ Georgopapadakou NH:Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob Agents Chemother 37:2045-2053, 1993

• ○ Dowson CG, Hutchison A, Brannigan JA et al:Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci USA 86:8842-8846, 1989
  pubmed

• ○ Ubukata K, Shibasaki Y, Yamamoto K et al:Association of amino acid substitution in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 45:1693-1699, 2001

P.270 掲載の参考文献

• ○ Welch RA, Forestier C, Lobo A et al:The synthesis and function of the Escherichia coli hemolysin and related RTX exotoxins. FEMS Microbiol Immunol 5:29-36, 1992
  pubmed

• ○ Tweten RK:Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 73:6199-6209, 2005
  pubmed

• ○ Zhang XH, Austin B:Haemolysins in Vibrio species. J Appl Microbiol 98:1011-1019, 2005
  pubmed

P.273 掲載の参考文献

• 1) Senda K, Arakawa Y, Nakashima K et al:Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 40:349-353, 1996

• 2) Walsh TR, Toleman MA, Poirel L et al:Metallo-β-lactamases:the quiet before the storm? Clin Microbiol Rev 18:306-325, 2005

• 3) Hirakata Y, Izumikawa K, Yamaguchi T et al:Rapid detection and evaluation of clinical characteristics of emerging multiple drug resistant gram-negative rods carrying the metallo-β-lactamase gene blaIMP. Antimicrob Agents Chemother 42:2006-2011, 1988

• 4) Hirakata Y, Yamaguchi T, Nakano M et al:Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis 37:26-32, 2003

P.275 掲載の参考文献

• 1) 小関至, 今井浩三:モノクローナル抗体の臨床研究概論日本臨牀 60:457-462, 2002

• ○ Morrison SL Johnson MJ, Herzenberg LA et al:Chimeric human antibody molecules:mouse antigenbinding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851-6855, 1984
  pubmed

• ○ Sievers EL, Appelbaum FR, Spielberger RT et al:Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy:a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684, 1999
  pubmed

• ○ Green LL, Hardy MC, Maynard-Currie CE et al:Antigen-specific monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7:13-21, 1994
  pubmed

P.277 掲載の参考文献

• 1) 後藤直正:病原細菌と外界を結ぶチャンネル 薬剤排出ポンプと病原因子分泌装置, 細菌のマルチコンポーネント型RND異物排出システム群の機能. 蛋白質・核酸・酵素 50:6-12, 2005

• ○ Piddock LJ:Multidrug-resistance efflux pumps-not just for resistance. Nat Rev Microbiol 4:629-636, 2006

• ○ Hirakata Y, Srikumar R, Poole K et al:Multidrug efflux systems play an important role in the invasiveness of Pseudommonas aeruginosa. J Exp Med 196:109-118, 2002
  pubmed

P.279 掲載の参考文献

• 1) Kimura T, Hashimoto I, Nishikawa M:HIV-1 Rev protein-an RNA adapter between the cis-acting viral target and the cellular CRM1/XPO1 nuclear export factor. In:Recent Research Developments in Biochemistry, ed. by Pandalai SG, Research Signpost, Kerala, 2003, pp. 519-548

• 2) Karn J, Asseline U, Churcher M et al:Transcriptional and post-transcriptional regulation of human immunodeficiency virus type-1 gene expression by the RNA-binding proteins Tat and Rev. In:Focus on HIV, ed. by Neu HC, Levy JA, Weiss RA, Churchill Livingstone, New York, 1993, pp. 98-129

• 3) 酒井博幸:14. HIV(3) HIV調節遺伝子による感染性の制御機構. ウイルス 52:89-94, 2002

• 4) Rossi JJ, June CH, Kohn DB:Genetic therapies against HIV. Nat. Biotechnol 25:1444-1454, 2007
  pubmed

P.281 掲載の参考文献

• ○ Chiarella P,Massi E, De Robertis M et al:Adjuvants in vaccines and for immunisation:current trends. Expert Opin Biol Ther 7:1551-1562, 2007
  pubmed

• ○ 特集 ワクチン開発と感染, 免疫-インフルエンザ・マラリア・HIV・SARS の制圧に向けて-. 細胞工学 23:762-816, 2004

• ○ 特集 ワクチン-感染症のコントロールに向けて-. 治療学 41:1001-1106, 2007

• ○ 國澤純, 真弓忠範:ワクチン療法におけるドラッグデリバリーシステムの応用-ウイルスの技術利用-. わかる実験医学シリーズ ウイルス・細菌と感染症がわかる, 吉開泰信編, 羊土社, 東京, 2004, pp. 78-84